Alexion Pharmaceuticals, Inc. (ALXN): Price and Financial Metrics

Alexion Pharmaceuticals, Inc. (ALXN)

Today's Latest Price: $113.72 USD

0.41 (-0.36%)

Updated Sep 18 4:00pm

Add ALXN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

ALXN Stock Summary

  • With a market capitalization of $24,924,351,627, Alexion Pharmaceuticals Inc has a greater market value than 92.13% of US stocks.
  • Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; only 14.94% of US stocks have a lower such ratio.
  • The volatility of Alexion Pharmaceuticals Inc's share price is greater than that of only 4.96% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Alexion Pharmaceuticals Inc are TEL, JAZZ, ELAN, FSLR, and COHR.
  • Visit ALXN's SEC page to see the company's official filings. To visit the company's web site, go to
ALXN Daily Price Range
ALXN 52-Week Price Range

ALXN Stock Price Chart Technical Analysis Charts

ALXN Price/Volume Stats

Current price $113.72 52-week high $121.50
Prev. close $114.13 52-week low $72.67
Day low $109.80 Volume 3,644,391
Day high $114.77 Avg. volume 2,252,064
50-day MA $106.64 Dividend yield N/A
200-day MA $104.35 Market Cap 24.92B

Alexion Pharmaceuticals, Inc. (ALXN) Company Bio

Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.

ALXN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$113.72$363.58 219%

We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 70th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 220.17% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for ALXN, they are:

  • The company has produced more trailing twelve month cash flow than 86.5% of its sector Healthcare.
  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than just 21.85% of the free cash flow producing stocks we're observing.
  • Alexion Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Alexion Pharmaceuticals Inc? See LCI, SGRY, UHS, ADUS, and MYL.

ALXN Latest News Stream

Event/Time News Detail
Loading, please wait...

ALXN Latest Social Stream

Loading social stream, please wait...

View Full ALXN Social Stream

Latest ALXN News From Around the Web

Below are the latest news stories about Alexion Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALXN as an investment opportunity.

We Think Alexion Pharmaceuticals (NASDAQ:ALXN) Can Manage Its Debt With Ease

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | September 16, 2020

Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis

Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.

Yahoo | September 15, 2020

A Look Into Alexion Pharmaceuticals's Price Over Earnings

In the current session, Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is trading at $108.21, after a 2.71% spike. Over the past …

Benzinga | September 14, 2020

A Look Into Alexion Pharmaceuticals's Price Over Earnings

In the current session, Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is trading at $108.21, after a 2.71% spike. Over the past month, the stock increased by 4.74%, and in the past year, by 0.35%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 10.94%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholde...

Yahoo | September 14, 2020

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Yahoo | September 14, 2020

Read More 'ALXN' Stories Here

ALXN Price Returns

1-mo 13.14%
3-mo -2.74%
6-mo 32.34%
1-year 6.96%
3-year -20.43%
5-year -28.59%
YTD 5.15%
2019 11.08%
2018 -18.59%
2017 -2.26%
2016 -35.86%
2015 3.09%

Continue Researching ALXN

Want to see what other sources are saying about Alexion Pharmaceuticals Inc's financials and stock price? Try the links below:

Alexion Pharmaceuticals Inc (ALXN) Stock Price | Nasdaq
Alexion Pharmaceuticals Inc (ALXN) Stock Quote, History and News - Yahoo Finance
Alexion Pharmaceuticals Inc (ALXN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0438 seconds.